MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Galecto ROA Ratio 2011-2026 | GLTO
Annual ROA Ratio Galecto
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -100.32 | -84.2 | -42.35 | -20.3 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.3 | -100.32 | -61.79 |
Quarterly ROA Ratio Galecto
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -87.38 | -74.81 | -69.26 | -53.03 | -69.29 | -68.93 | -67.65 | -54.63 | -71.37 | -71.85 | -69.13 | -47.84 | -57.18 | -34.24 | -42.62 | -26.13 | -32.92 | -30.37 | -25.45 | -13.56 | -20.81 | -21.27 | -17.81 | -7.25 | -7.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.25 | -87.38 | -45.68 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alnylam Pharmaceuticals
ALNY
|
-6.56 | $ 322.7 | 0.84 % | $ 41.2 B |  USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
-40.29 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Amarin Corporation plc
AMRN
|
-7.11 | $ 15.14 | 2.61 % | $ 6.17 B |  Irlanda |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.84 | 2.78 % | $ 4.58 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
-37.44 | $ 2.95 | 10.57 % | $ 166 M | China |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
AlloVir
ALVR
|
-49.57 | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.51 | -1.68 % | $ 8.45 B |  Australia |
 |
BioNTech SE
BNTX
|
65.02 | $ 110.14 | -0.18 % | $ 27.2 B | Germany |
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
Cabaletta Bio
CABA
|
-26.68 | $ 2.62 | 7.38 % | $ 3.06 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Compugen Ltd.
CGEN
|
-12.38 | $ 1.79 | 4.39 % | $ 160 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-34.19 | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
-251.11 | - | -45.71 % | $ 1.2 M | Canada |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-35.36 | $ 222.04 | - | $ 5 B |  Danmark |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
16.8 | $ 41.27 | -0.1 % | $ 4.26 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
19.25 | $ 24.19 | -1.06 % | $ 2.87 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
-78.56 | - | -6.81 % | $ 3.04 B | USA |
|
Champions Oncology
CSBR
|
14.53 | $ 6.41 | -2.14 % | $ 87.6 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 9.18 | 2.34 % | $ 1.48 B | Britain |
 |
Aridis Pharmaceuticals
ARDS
|
-206.68 | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Athira Pharma
ATHA
|
-164.92 | - | - | $ 269 M | USA |
 |
Athersys
ATHX
|
-144.48 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 4.54 | 7.58 % | $ 9.88 B | Israel |
 |
Precision BioSciences
DTIL
|
-38.38 | $ 3.77 | -1.05 % | $ 14.5 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.46 | -0.34 % | $ 373 M | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
-2.11 | $ 14.73 | 1.41 % | $ 4.55 B | USA |
 |
Codexis
CDXS
|
-43.81 | $ 1.27 | -1.55 % | $ 93.2 M | USA |